
Denifanstat Hits All Targets in Chinese Study
Today, Ascletis Pharma has announced promising phase III trial results for denifanstat (ASC40), its oral fatty acid synthase (FASN) inhibitor, in the treatment of moderate to severe acne vulgaris. The randomized, double-blind, placebo-controlled study …